Compare CLOV & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLOV | CTMX |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 977.1M |
| IPO Year | 2020 | 2015 |
| Metric | CLOV | CTMX |
|---|---|---|
| Price | $1.93 | $4.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $2.90 | ★ $12.10 |
| AVG Volume (30 Days) | 5.4M | ★ 11.2M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.03 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,924,308,000.00 | $76,201,000.00 |
| Revenue This Year | $52.59 | N/A |
| Revenue Next Year | $15.37 | $18.75 |
| P/E Ratio | ★ N/A | $22.58 |
| Revenue Growth | ★ 40.34 | N/A |
| 52 Week Low | $1.58 | $0.53 |
| 52 Week High | $3.92 | $8.21 |
| Indicator | CLOV | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 52.01 | 45.84 |
| Support Level | $1.58 | $3.89 |
| Resistance Level | $2.78 | $4.54 |
| Average True Range (ATR) | 0.10 | 0.29 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 80.23 | 41.14 |
Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.